Sangamo Therapeutics's total assets for Q1 2026 were $59.97M, an increase of 0.37% from the previous quarter. SGMO total liabilities were $78.92M for the fiscal quarter, a 6.63% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.